OSR HOLDINGS INC (OSRH) Stock Price, Forecast & Analysis
USA - NASDAQ:OSRH - US68840D1028 - Common Stock
OSRH Key Statistics, Chart & Performance
The current stock price of OSRH is 0.5699 USD. In the past month the price increased by 2.41%.
OSRH Latest News, Press Relases and Analysis
OSRH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.28B | ||
| AMGN | AMGEN INC | 15.34 | 180.66B | ||
| GILD | GILEAD SCIENCES INC | 14.91 | 151.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.49 | 109.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.91 | 71.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 888.88 | 59.42B | ||
| INSM | INSMED INC | N/A | 40.69B | ||
| NTRA | NATERA INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 9.45 | 23.18B | ||
| INCY | INCYTE CORP | 16.85 | 21.13B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.56 | 20.96B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.5 | 14.72B |
Related stock screener links
About OSRH
Company Profile
OSR Holdings, Inc. operates as a blank check company. The company is headquartered in Bellevue, Washington. The company went IPO on 2023-02-10. The firm is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The firm's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The firm has operations in Europe and South Korea.
Company Info
OSR HOLDINGS INC
10900 Ne 4Th Street, Suite 2300
Bellevue WASHINGTON US
Employees: 0
Phone: 14256357700
OSR HOLDINGS INC / OSRH FAQ
Can you describe the business of OSR HOLDINGS INC?
OSR Holdings, Inc. operates as a blank check company. The company is headquartered in Bellevue, Washington. The company went IPO on 2023-02-10. The firm is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The firm's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The firm has operations in Europe and South Korea.
What is the stock price of OSR HOLDINGS INC today?
The current stock price of OSRH is 0.5699 USD. The price decreased by -1.33% in the last trading session.
What is the dividend status of OSR HOLDINGS INC?
OSRH does not pay a dividend.
What is the ChartMill rating of OSR HOLDINGS INC stock?
OSRH has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in OSR HOLDINGS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OSRH.
Can you provide the ownership details for OSRH stock?
You can find the ownership structure of OSR HOLDINGS INC (OSRH) on the Ownership tab.
OSRH Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OSRH.
OSRH Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OSRH. Both the profitability and financial health of OSRH have multiple concerns.
OSRH Financial Highlights
Over the last trailing twelve months OSRH reported a non-GAAP Earnings per Share(EPS) of -1.69. The EPS decreased by -298.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.18% | ||
| ROE | -15.91% | ||
| Debt/Equity | 0.05 |